- Investing.com
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, and thoracic surgery staining location; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China.
Metrics to compare | 2216 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2216PeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.3x | 5.8x | −0.6x | |
PEG Ratio | −0.36 | 0.29 | 0.00 | |
Price/Book | 1.0x | 2.8x | 2.6x | |
Price / LTM Sales | 25.6x | 2.8x | 3.4x | |
Upside (Analyst Target) | −33.2% | 21.2% | 42.0% | |
Fair Value Upside | Unlock | 12.9% | 5.8% | Unlock |